Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia

American Journal of Hematology

Volumn 83, Issue 6, 2008, Pages 446-450

  Hussein, Kebede ^a   Jahagirdar, Balkrishna ^a   Gupta, Pankaj ^a   Burns, Linda ^a   Larsen, Karen ^a   Weisdorf, Daniel ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE; ETOPOSIDE; FLUDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; CHEMOTHERAPY; CYTOCHEMISTRY; CYTOGENETICS; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLAST CRISIS; BONE MARROW EXAMINATION; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 44349125636     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21133     Document Type: Article

References (31)

1. Brincker H. Estimates of overall treatment results in acute non-lymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat Rep 1985;69:5-11.
2. Holland JF, Gildewell O, Ellison RR, et al. Acute myelocytic leukemia. Arch Intern Med 1976;136:1377-1381.
3. Bennett JM, Young ML, Anderson JW, et al. Long-term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group experience. Cancer 1997;80(Suppl):2205-2209.
4. Vey N, Coso D, Bardou VJ, et al. The benefit of induction chemotherapy in patients age ≥ 75 years. A retrospective study of 110 patients from a single institution. Cancer 2004;101:325-331.
5. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Ash Educational Program Book. Hematology 2004;1:98-117.
6. Tallman MS. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Ash Educational Program Book. Hematology 2005;1:143-150.
7. Dunphy CH. Comprehensive review of adult acute myelogenous leukemia: Cytomorphological, enzyme cytochemical, flow cytometric immunophenotypic, and cytogenetic findings. J Clin Lab Anal 1999;13:19-26.
8. Stein RS, Wolff SN, Greer JP, et al. Age and cytogenetics as predictors of event free survival in patients with acute non-lymphocytic leukemia receiving high dose arabinoside and daunorubicin as consolidation chemotherapy. Leuk Lymphoma 2001;42:913-922.
9. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 106:1154-1163.
10. Preisler H, Bracos M, Reese P, et al. Recognition of drug resistance during remission induction therapy for acute non-lymphocytic leukemia: Utility of day 6 bone marrow biopsy. Leuk Res 1983;7:67-75.
11. Roberts MM, Juttner CA, To LB, et al. Bone marrow biopsy during induction chemotherapy for acute myeloid leukemia identifies only 50% of patients with resistant disease. Leuk Res 1988;12:817-821.
12. Browman G, Prisler H, Raza A, et al. Use of day 6 bone marrow to alter remission induction therapy in patients with AML: A leukemia intergroup study. Br J Haematol 1989;71:493-497.
13. Hammerschmidt DE, Crea MTW. Anthracycline-based therapy of de novo acute myeloid leukemia in adults: Failure of first-cycle cytoreduction to predict second-cycle outcome. Am J Hematol 1994;47:172-177.
14. Cassileth PA, Gerson SL, Bonner H, et al. Identification of early relapse patients with adult acute nonlymphocytic leukemia by bone marrow biopsy after initial induction chemotherapy. J Clin Oncol 1984;2:107-111.
15. Campana D, Pui C-H. Detection of minimal residual disease in acute leukemia: Methodological advances and clinical significance. Blood 1995;85:1416-1434.
16. Meyerson HJ, Farhi DC, Rosenthal NS. Transient increase in blasts mimicking acute leukemia and progressing myelodysplasia in patients receiving growth factor. Am J Clin Pathol 1998;109:675-681.
17. Ries L, Eisner M, Kosary C, et al. U.S. Government statistics. Surveillance, epidemiology, and end-results (SEER) of the National Cancer Institute; 2005. SEER Cancer Statistics Review, 1975-2001, NIH. Available at: http://seer.cancer.gov/csr/ 1975_2001/. Bethesda, MD: National Cancer Institute; Accessed December 2004.
18. Stalfelt AM, Brodin H, Petterson S, et al. The final phase in AML: A study of cause of death, place of death and type of care during the last week of life. Leuk Res 2001;25:673-680.
19. Nannya Y, Kanda Y, Oshima K, et al. Prognostic factors in elderly patients with acute myelogenous leukemia: A single center study in Japan. Leuk Lymphoma 2002;43:83-87.
20. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481-3485.
21. Lopez A, Rubia JDA, Martin G, et al. Recent improvements in outcome for elderly patients with de novo acute myeloblasts leukemia. Leuk Res 2001;25: 685-692.
22. Oki Y, Kantarjian HM, Zhou X, et al. Adultacute megakaryocyte leukemia: An analysis of 37 patients treated at MD Anderson Cancer Center. Blood 2006;107:880-884.
23. Latagliata R, Alimena G, Carmosino I, et al. Conservative treatment for patients over 80 years with acute myeloid leukemia. Am J Hematol 2002; 71:256-259.
24. Behringer B, Pitako JA, Kunzmann R, et al. Prognosis of older patients with acute leukemia receiving either induction or noncurative treatment: A single center retrospective study. Ann Hematol 2003;82:381-389.
25. Schmitz LL, Litz CE, Brunning RD. Morphologic and quantitative alterations in hematopoietic cells associated with growth factor therapy: Review of the literature. Hematol Pathol 1994,8:55-73.
26. Kerrigan DP, Castillo A, Foucar K, et al. Peripheral blood morphological changes after high-dose antineoplastic chemotherapy and recombinant human granulocyte colony-stimulating factor administration. Am J Clin Pathol 1989;92:280-285.
27. Schmitz LL, McClure JS, Litz CE, et al. Morphologic and quantitative changes in blood and marrow cells following growth factor therapy. Am J Clin Pathol 1994;101:67-75.
28. Bacher U, Kern W, Schoch C, et al. Evaluation of complete disease remission in acute myeloid leukemia: A prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia. Cancer 2006; 106:839-647.
29. Cheson BD, Bennet JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia and evaluation of complete disease remission in acute myeloid leukemia. J Clin Oncol 2003;21:4642-4649.
30. Slovak ML, Kopecky KJ, Cassileth PA, et al., for the Southwest Oncology Group and the Eastern Cooperative Oncology Group. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000;96:4075-4083.
31. Altman DG, Bland JM. Diagnostic tests 2 - Predictive values. Br Med J 1994;309:102.